Collaborative Arrangements and Licensing Agreements (Tables)

9 Months Ended

Sep. 30, 2018

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Three Months Ended September 30,								Nine Months Ended September 30,
	2018				2017				2018				2017
R&D revenue		$	14.2			$	4.8			$	86.5			$	14.8
Percentage of total revenue			10	%			4	%			21	%			4	%

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
SPINRAZA royalties (commercial revenue)	$	70.0		$	32.9		$	167.7		$	60.5
R&D revenue		34.8			54.9			66.9			137.1
Total revenue from our relationship with Biogen		104.8			87.8			234.6			197.6
Percentage of total revenue		72	%		74	%		58	%		57	%

Bayer [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):

	Three Months Ended September 30,								Nine Months Ended September 30,
	2018				2017				2018				2017
R&D revenue		$	1.9			$	0.4			$	3.3			$	66.0
Percentage of total revenue			1	%			0	%			1	%			19	%

Janssen Biotech, Inc. [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):

	Three Months Ended September 30,								Nine Months Ended September 30,
	2018				2017				2018				2017
R&D revenue		$	0.9			$	3.4			$	6.6			$	18.1
Percentage of total revenue			1	%			3	%			2	%			5	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):

	Three Months Ended September 30,								Nine Months Ended September 30,
	2018				2017				2018				2017
R&D revenue		$	7.2			$	9.9			$	42.7			$	21.7
Percentage of total revenue			5	%			8	%			10	%			6	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Three Months Ended September 30,								Nine Months Ended September 30,
	2018				2017				2018				2017
R&D revenue		$	1.8			$	4.5			$	5.4			$	5.9
Percentage of total revenue			1	%			4	%			1	%			2	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):

	Three Months Ended September 30,								Nine Months Ended September 30,
	2018				2017				2018				2017
R&D revenue		$	0.1			$	4.6			$	1.5			$	14.4
Percentage of total revenue			0	%			4	%			0	%			4	%

PTC Therapeutics [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with PTC (in millions, except percentage amounts):

	Three Months Ended September 30,							Nine Months Ended September 30,
	2018				2017			2018				2017
R&D revenue		$	12.0			$	0.0		$	12.0			$	0.0
Percentage of total revenue			8	%			—			3	%			—